黄芩胶囊辅助头孢哌酮舒巴坦替加环素治疗MDRAB肺炎的效果及安全性分析

Analysis on the Effects and Safety of Huangqi Capsule Assisted with Cefoperazone-sulbactam and Tigecycline in the treatment of MDRAB Pneumonia

目的:探究黄芩胶囊辅助头孢哌酮舒巴坦、替加环素治疗多重耐药鲍氏不动杆菌(MDRAB)肺炎的效果及安全性。方法:回顾性分析我院给予头孢哌酮舒巴坦+替加环素治疗(对照组)及予以黄芩胶囊+头孢哌酮舒巴坦+替加环素治疗(观察组)的MDRAB肺炎患者各52例临床资料。记录两组细菌清除情况、病情恢复情况(体温恢复正常时间、啰音消失时间、肺部阴影消失时间)、治疗期间不良反应发生状况,并比较两组治疗前及治疗2周后感染状况[降钙素原(PCT)、基质金属蛋白酶-9(MMP-9)]、中医证候[中医证候评分量表(TCMSSS)]、肺部损伤[肺损伤评分(LIS)]差异。结果:观察组细菌清除情况明显优于对照组(P<0.05),体温恢复正常时间、啰音消失时间、肺部阴影消失时间及治疗期间不良反应总发生率明显低于对照组(P<0.05)。治疗2周后,两组感染状况(血清PCT、MMP-9)、中医证候(TCMSSS评分)、肺部损伤(LIS评分)均较治疗前降低(P<0.05),且观察组低于对照组(P<0.05)。结论:黄芩胶囊辅助头孢哌酮舒巴坦、替加环素治疗MDRAB肺炎效果显著,还能减少不良反应发生风险,临床应用价值较高。

Objective:To explore the effects and safety of Huangqi capsule combined with cefoperazone-sulbactam and tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii(MDRAB)pneumonia.Methods:The clinical data of 52 cases of MDRAB pneumonia treated with cefoperazone sulbactam+tegacyclin(control group)and Huangqin capsule+cefoperazone sulbactam+tegacyclin(observation group)were analyzed retrospectively.The bacterial clearance,state of recovery(time of normal temperature recovery,Rale disappearance,lung shadow disappearance)and adverse reactions were recorded,and the infection status(PCT,MMP-9),TCM syndrome(tcmsss),lung injury(lung injury)were compared before and after treatment for 2 weeks Score(LIS)difference.Results:The bacterial clearance in observation group was significantly better than that in control group(P<0.05),and the normal recovery time of body temperature,disappearance time of rales,disappearance time of lung shadow and total incidence rate of adverse reactions during treatment were significantly lower than those in control group(P<0.05).After 2周of treatment,the scores of infection status(serum PCT,MMP-9),TCM syndrome(TCMSSS score)and lung injury(LIS score)were lower than those before treatment(P<0.05),and the scores in observation group were lower than those in control group(P<0.05).Conclusion:Huangqi capsule assisted with cefoperazone-sulbactam and tigecycline has significant effects in the treatment of MDRAB pneumonia,and it can also reduce the risk of adverse reactions and has high clinical application value.